Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| Nutriworks | INDUSTRY |
Not provided
Not provided
Not provided
Not provided
The goal of this clinical trial is to find usefulness of balanced high protein supplementation on muscle function recovery and clinical outcomes after chemotherapy.
Participants will intake test or placebo oral nutritional supplements. Researchers will compare test groups and placebo groups to see if test oral supplements are more useful in muscle function recovery and clinical outcomes.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Control group | Placebo Comparator | Subjects will receive two packs of placebo ONS (ONS_320275) orally daily |
|
| Test group | Experimental | Subjects will receive two packs of test ONS (ONS_211567) orally daily |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| ONS_320275 | Other | Subjects will consume two packs (165ml/pack) of placebo ONS (ONS_320275) orally daily at any time of day. |
|
| Measure | Description | Time Frame |
|---|---|---|
| Skeletal Muscle Index (SMI) change rate | Skeletal Muscle analysis is performed using BIA. | Change rate from baseline Skeletal Muscle Index (SMI) at 12 weeks |
| Measure | Description | Time Frame |
|---|---|---|
| Sarcopenia prevalence | Muscle reduction is determined by the researcher through SMM, HGS, and SPPB test results. | Change from baseline Muscle reduction at 12 weeks |
| Skeletal muscle mass (SMM) | Skeletal muscle mass (SMM) analysis is performed using BIA. |
Not provided
Inclusion Criteria:
Exclusion Criteria:
A person who has previously been diagnosed with cancer
A person with a BMI of 30.0 kg/m2 or more
A person who is diabetes mellitus with whose blood sugar is not controlled even when taking medication
A person diagnosed with hypertension whose blood pressure is not controlled even when taking medication
A person with renal dysfunction (up 1.5 times the upper limit of Creatinine normal) and liver dysfunction (up 2.5 times the upper limit of AST and ALT normal)
A person with a serious musculoskeletal problem
A person who has been diagnosed with acute or serious diseases (e.g., liver, kidney, heart, thyroid disease, etc.) or is on medication
A person who has continuously taken health functional foods related to the ability to perform exercise within three months before visiting (Hormones, muscle enhancers, protein supplementation and muscle function improvement)
A person who is allergic or overreacting to the ingredients of a test product
A person who has participated in another clinical trial or a drug clinical trial within one month of the commencement of this test
A person who is illiterate or whose ability is limited
A person who is pregnant or lactating
A person judged inappropriate by a researcher to participate in this study for other reasons
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Joo Hyun Park | Contact | (+82) 80-996-6262 | jhpark3@daesang.com |
Not provided
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Seoul St. Mary's hospital | Recruiting | Seoul | 06591 | South Korea |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D015179 | Colorectal Neoplasms |
| ID | Term |
|---|---|
| D007414 | Intestinal Neoplasms |
| D005770 | Gastrointestinal Neoplasms |
| D004067 | Digestive System Neoplasms |
| D009371 | Neoplasms by Site |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ONS_211567 | Other | Subjects will consume two packs (165ml/pack) of test ONS (ONS_211567) orally daily at any time of day. |
|
| Change from baseline Skeletal muscle mass (SMM) at 12 weeks |
| Handgrip strength (HGS) | Handgrip strength (HGS) is an indicator of muscle strength. | Change from baseline Handgrip strength (HGS) at 12 weeks |
| Short physical performance battery (SPPB) | Short physical performance battery (SPPB) is a multi-function evaluation that combines three useful and easy-to-measure objective functional evaluation methods. | Change from baseline Short physical performance battery (SPPB) at 12 weeks |
| Common terminology criteria for adverse events (CTCAE) 5.0 | Common Terminology Criteria for Adverse Events (CTCAE) is widely accepted as the standard classification and severity grading scale for adverse events in cancer therapy, clinical trials and other oncology settings. Version 5.0 is the most updated document. | Evaluating from 6 weeks to 12 weeks |
| Incidence of chemotherapy modification | Incidence of chemotherapy modification is classified into delayed administration, dose reduction, and administration termination of anticancer drugs, and investigated on a dichotomy scale (existence or absence). | Evaluating from 6 weeks to 12 weeks |
| Weight change and weight change rate | Weight analysis is performed using BIA. | Change from baseline weight change and weight change rate at 12 weeks |
| Detection of immunity indicators in blood samples drawn from a vein | Detection and quantification of immunity indicators in blood samples drawn from a vein : Interleukin-6 (IL-6), Interleukin 10 (IL-10), Interleukin 17 (IL-17), Interleukin-2 (IL-2), Interleukin-12 (IL-12), Interferon gamma (IFN-γ), Tumor necrosis factor-alpha (TNF-α) | Change from baseline immunity indicators at 12 weeks |
| Nutritional status evaluation and intake evaluation (PG-SGA) | Nutritional status evaluation and intake evaluation (PG-SGA) is a tool that expresses nutritional status. It is divided into continuous and categorical variables. In continuous variable, 0 to 1 point is said to be good according to the total score, and 2 to 3, 4 to 8, and 9 or more points are evaluated as 3 phases of malnutrition. In categorical variable, it consists of three types: A, B, and C, and the results deteriorate in order. | Change from baseline PG-SGA score at 12 weeks |
| Quality of life (EORTC QLQ-C30) | Quality of life (EORTC QLQ-C30) is developed to assess the quality of life of cancer patients. Each questions 1 through 28 have a maximum of 4 point and a minimum of 1 point, and each questions 29 through 30 have a maximum of 7 point and a minimum of 1 point. The former means higher scores is worse results, and the latter means higher scores is better results. The total score is 0 to 100 points. | Change from baseline EORTC QLQ-C30 score at 12 weeks |
| Simplified nutritional appetite questionnaire (SNAQ) | Simplified nutritional appetite questionnaire (SNAQ) is a simple appetite scale assessment tool that has been validated to predict weight loss in cancer patients. Including all the questions, each question's maximum score is 5 point and the minimum score is 1 point. A lower score means worse results. The total score is 4 to 20 points. | Change from baseline SNAQ score at 12 weeks |
| Oral nutritional supplement (ONS) sensory evaluation | Oral nutritional supplement (ONS) sensory evaluation is sensuality evaluation of test or control products. | Evaluating from 6 weeks to 12 weeks |
| D009369 | Neoplasms |
| D004066 | Digestive System Diseases |
| D005767 | Gastrointestinal Diseases |
| D003108 | Colonic Diseases |
| D007410 | Intestinal Diseases |
| D012002 | Rectal Diseases |